* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

Novo-Nordisk

Biotech Stocks: Pfizer, Novo Nordisk, Sanofi lead drug-stock rally

marketwatch.com
Sep 19, 2008 2 related
        

By Val Brickates Kennedy, MarketWatch BOSTON (MarketWatch) -- Drug stocks were on a roll Friday, as the broader market rallied after spending the better part of the week deep in negative territory. The Amex Pharmaceutical...

add comment

Maxygen Lands $170M Preclinical Deal with Astellas

tmcnet.com
Sep 19, 2008 2 related
        

Less than three months after selling preclinical hemophilia drug MAXY-VII to Bayer HealthCare in a deal worth up to $120 million, Maxygen Inc. is at it again. This time, the Redwood City, Calif.-based biotech signed a...

add comment

Phase Forward to Present at the UBS Global Life Sciences Conference

finanznachrichten.de
Sep 18, 2008 1 related
        

Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its chief executive officer and president, Bob Weiler, and chief financial...

add comment

Aegis Therapeutics Awarded Patent for Its ProTek(R) Room Temperature Stable Human Growth Hormone...

marketwire.com
Sep 16, 2008 1 related
        

SAN DIEGO, CA--(Marketwire - September 16, 2008) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent 7,425,542, titled "Stabilizing alkylglycoside compositions and methods thereof." The patent...

add comment
                   

Transition Therapeutics Announces Fiscal 2008 Year End Financial Results

tmcnet.com
Sep 15, 2008 2 related
        

Attention Business/Financial Editors TORONTO, Sept. 15 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH, NASDAQ:TTHI) a product-focused biopharmaceutical company developing therapeutics for...

add comment

Amylin shares rise as Icahn boosts ownership stake

ibtimes.com
Sep 15, 2008 3 related
        

NEW YORK - Shares of biotechnology company Amylin Pharmaceuticals Inc. jumped Monday following billionaire investor Carl Icahn's move to increase his ownership stake to 7.3 percent. The stock advanced 95 cents, or 4.7...

add comment
                   

'Mad Money Lightning Round': First Solar Shines (at TheStreet.com)

yahoo.com
Sep 15, 2008 3 related
        

Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Thursday evening: First Solar : "I like the technology and I'm a buyer of First Solar. Jim Cramer,...

add comment

Your First Move For Tuesday Sept. 9th (at CNBC)

yahoo.com
Sep 15, 2008 3 related
        

Here’s our Fast Money Final Trade. Our gang gives you tomorrow’s best trades, right now. Jeff Macke suggests RIMM is a “Buy at $100 with a tight stop at $95." Guy Adami prefers long Urban Outfitters . Karen Finerman likes...

add comment

Biotech Stocks: Drug stocks follow broader market into red

marketwatch.com
Sep 15, 2008 4 related
        

BOSTON (MarketWatch) - Drug stocks followed the broader market into negative territory early Monday as investors grappled with news that one of the U.S.'s largest financial institutions, Lehman Brothers, has filed for...

add comment
                   

“Children with diabetes lack support at school”

hindu.com
Sep 13, 2008 2 related
        

ROME: Nine out of 10 children with diabetes lack support at school, the results of an international survey conducted in 13 countries during 2007-2008 and launched here recently, have revealed. Presented on the sidelines...

add comment